Zobrazeno 1 - 10
of 49
pro vyhledávání: '"J Ortiz de Zárate"'
Autor:
Ana Garre, E Fernández Salgado, Hernández, X. Calvet, M. Barreiro-de Acosta, M T Diz-Lois Palomares, María José Casanova, José Luis Cabriada, Luis Fernández-Salazar, M Vela, Lara Arias, M Navarro-Llavat, María Chaparro, Á Ponferrada Díaz, E Guerra del Río, Sabino Riestra, E Sánchez Rodríguez, R. Vicente, P. Varela Trastoy, Mariam Aguas, Daniel Ginard, M Sierra, Corina Iris Rodriguez, José María Huguet, Miguel Rivero, M D Martin-Arranz, Isabel Vera-Mendoza, Pablo Navarro, Patricia Vega, K Spicakova, Jesus Barrio, R Ferreiro-Iglesias, J Ortiz de Zárate, Ana Echarri, José Manuel Benítez, Inmaculada Alonso-Abreu, Javier P. Gisbert, Fernando Gomollón, A Núñez Ortiz, H Alonso-Galán
Publikováno v:
Journal of Crohn's and Colitis. 15:S018-S020
Background The management of inflammatory bowel disease (IBD) has substantially changed in the last decades, both in relation to medical and surgical treatments. Aims Principal: To know the rate of surgery in a newly diagnosed IBD cohort within the f
Autor:
C Muñoz-Villafranca, P Arreba, M Gomez, N Ispizua Madariaga, L Buendia, M L Lopez, A Ugarte, I de la Fuente, N Prado, L Irusta, M A Jimenez, M Santa Cruz, M Gonzalez, A Bilbao, J Ortiz de Zárate
Publikováno v:
Journal of Crohn's and Colitis. 17:i723-i723
Background The usefulness of therapeutic drug monitoring(TDM) of infliximab during induction and its relationship with clinical outcome in patients with inflammatory bowel disease(IBD) is well established. However, the optimal time of monitoring in t
Autor:
U Aresti Goiriena, M Irigoyen Muñoz, Á J Calderón García, C Muñoz-Villafranca, N A Rivera Garcia, J Ortiz de Zárate, P. Arreba González, N Ispizua
Publikováno v:
Journal of Crohn's and Colitis. 15:S148-S149
Background Currently,endoscopy,an invasive medical procedure, is the gold standard for diagnosis of inflammatory bowel disease (IBD) and to determine mucosal activity.Our main goal was to identify biomarkers in saliva samples that can be used as a sc
Autor:
L Ramos, Jordina Llaó, E Sesé, M Durà, M. Chaparro, Montserrat Aceituno, P Gilabert, Paola Varela, M F García-Sepulcre, G Suris, Ignacio Marín-Jiménez, L Olivan, Yago González-Lama, J Ortiz de Zárate, José María Huguet, E. Iglesias, Laura Jiménez, I Rodríguez-Lago, E Hinojosa, Fernando Muñoz, Alejandro Hernández-Camba, R Plaza-Santos, F Ramírez Esteso, Cristina Alba, S Estrecha, A Brotons, M Piqueras, Y. Zabana Abdo, José Luis Cabriada, N Rull, A. Lopez-San Roman, M Sierra, E. Domènech, A Fuentes Coronel, Fernando Gomollón, M Esteve, Daniel Carpio, S. Meijilde, A Gutiérrez, Daniel Ginard
Publikováno v:
Journal of Crohn's & Colitis
JOURNAL OF CROHNS & COLITIS
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
r-FISABIO. Repositorio Institucional de Producción Científica
JOURNAL OF CROHNS & COLITIS
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
r-FISABIO. Repositorio Institucional de Producción Científica
Background The exhaustive registry of COVID-19 cases in patients with IBD is a unique opportunity to learn how to deal with this infection, especially in reference to the management of immunosuppressive treatment, isolation measures or if the disease
Autor:
M L Garcia-Vivar, M Irigoyen, A Bilbao, Gastro-Reuma, Nerea Hernandez-Aretxabaleta, C Garcia-Gomez, J Ortiz de Zárate, C Muñoz-Villafranca, Paz Arreba, U Aresti, Martin Irabien
Publikováno v:
Journal of Crohn's and Colitis. 15:S281-S282
Background Drug-induced lupus (DIL) has been described as an adverse event of an immunological nature, in relation to treatment with anti-TNFα drugs. It is considered as a manifestation uncommon in patients with inflammatory bowel disease (IBD). The
Autor:
B Álvarez-Herrero, S De La Maza-Ortiz, U Aresti, J M Gómez-Zabala, Paz Arreba, M Irigoyen, P Ramírez de la Piscina, A Loizate, I Gorostiza, J Ortiz de Zárate, C Muñoz-Villafranca, M Á Ogueta
Publikováno v:
Journal of Crohn's and Colitis. 15:S475-S475
Background Infliximab is effective as rescue therapy in moderate-severe Ulcerative Colitis (UC). Subsequently, a biosimilar of infliximab has been approved for the same indications, as its effectiveness is considered similar to the original inflixima
Autor:
A. B. Díaz Roca, A. Calderón, S. Blanco, P. Ruiz, J. Ortiz de Zárate, F. Menéndez, A. Baranda, M. Bravo, L. Hijona, V. Orive
Publikováno v:
Revista Espanola de Enfermedades Digestivas, Vol 101, Iss 4, Pp 298-299 (2009)
Externí odkaz:
https://doaj.org/article/50731d7b9deb43b5948490d904532156
Autor:
P. Ruiz, F. Obregón, J. Ortiz de Zárate, P. Cabezudo, F. Polo, L. Marcé, S. Blanco, O. Gorriño, A. G. Bolado, I. Lecumberri, V. Orive
Publikováno v:
Revista Espanola de Enfermedades Digestivas, Vol 97, Iss 5, Pp 383-384 (2005)
Externí odkaz:
https://doaj.org/article/089697d69c114385b8ab4baa59e83ce5
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
J. Heras Martín, I. García Kamiruaga, P. Cabezudo Gil, V. Orive Cura, J Ortiz de Zárate, C. Muñoz Villafranca, P. Arreba González, M.T. Bravo Rodríguez
Publikováno v:
Journal of Crohn's and Colitis. 8:S234-S235